Multimarker Approach in Discriminating Patients with Symptomatic and Asymptomatic Atherosclerotic Carotid Artery Stenosis.
- Author:
Piotr MUSIALEK
1
;
Wieslawa TRACZ
;
Lukasz TEKIELI
;
Piotr PIENIAZEK
;
Anna KABLAK-ZIEMBICKA
;
Tadeusz PRZEWLOCKI
;
Ewa STEPIEN
;
Przemyslaw KAPUSTA
;
Rafal MOTYL
;
Jakub STEPNIEWSKI
;
Anetta UNDAS
;
Piotr PODOLEC
Author Information
- Publication Type:Original Article
- Keywords: carotid artery stenosis; biomarkers; circulating cytokines; risk factors; stroke risk; HDL-cholesterol
- MeSH: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adiponectin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Chemokine CCL2; Cholesterol; Constriction, Pathologic; Cytokines; Discrimination (Psychology); Fibrinogen; Humans; Interleukin-18; Interleukin-6; Interleukin-8; Leptin; Lipoprotein(a); Lipoproteins; Logistic Models; Nicotinamide Phosphoribosyltransferase; Odds Ratio; Osteoprotegerin; Peroxidase; Plaque, Atherosclerotic; Prospective Studies; Risk Factors; ROC Curve; Rupture; Triglycerides; Vascular Cell Adhesion Molecule-1
- From:Journal of Clinical Neurology 2013;9(3):165-175
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND PURPOSE: Several circulating biomarkers have been implicated in carotid atherosclerotic plaque rupture and thrombosis; however, their clinical utility remains unknown. The aim of this study was to determine the role of a large biomarker panel in the discrimination of symptomatic (S) vs. asymptomatic (A/S) subjects in a contemporary population with carotid artery stenosis (CS). METHODS: Prospective sampling of circulating cytokines and blood lipids was performed in 300 unselected, consecutive patients with > or =50% CS, as assessed by duplex ultrasound (age 47-83 years; 110 with A/S and 190 with S) who were referred for potential CS revascularization. RESULTS: CS severity and pharmacotherapy did not differ between the A/S and S patients. The median values of total cholesterol, low-density lipoprotein cholesterol, and lipoprotein(a) did not differ, but high-density lipoprotein (HDL) cholesterol was significantly higher (p<0.001) and triglycerides were lower (p=0.03) in the A/S-CS group than in the S-CS group. Interleukin-6 (IL-6) and high-sensitivity C-reactive protein were higher (p=0.04 and p=0.07, respectively) in the S-CS group. Circulating visfatin, soluble CD 40 receptor ligand, soluble vascular cell adhesion molecule, leptin, adiponectin, IL-1beta, IL-8, IL-18, monocyte chemoattractant protein-1, myeloperoxidase, matrix metalloproteinases-8, -9, and -10, and fibrinogen were similar, but tissue inhibitor of matrix metalloproteinases-1 (TIMP) was reduced in S-CS compared to A/S-CS (p=0.02). Nevertheless, incorporation of TIMP and IL-6 did not improve the HDL-cholesterol receiver operating characteristics for S-CS status prediction. S-CS status was unrelated to angiographic stenosis severity or plaque burden, as assessed by intravascular ultrasound (p=0.16 and p=0.67, respectively). Multivariate logistic regression analysis revealed low HDL-cholesterol to be the only independent predictor of CS symptoms, with an odds ratio of 1.81 (95% confidence interval=1.15-2.84, p=0.01) for HDL <1.00 mmol/L (first quartile) vs. >1.37 (third quartile). In S-CS, osteoprotegerin and lipoprotein-associated phospholipase A2 (Lp-PLA2) were elevated in those with recent vs. remote symptoms (p=0.01 and p=0.02, respectively). CONCLUSIONS: In an all-comer CS population on contemporary pharmacotherapy, low HDL-cholesterol (but not other previously implicated or several novel circulating biomarkers) is an independent predictor of S-CS status. In addition, an increase in circulating osteoprotegerin and Lp-PLA2 may transiently indicate S transformation of the carotid atherosclerotic plaque.
